Current | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000

Celera Corporation Fourth Quarter and 2010 Results and Conference Call Scheduled for March 10, 2011

ALAMEDA, CA - March 03, 2011

Celera Corporation (NASDAQ:CRA) announced today that it will issue fourth quarter and 2010 financial results on Thursday, March 10, 2011. Results are scheduled for release after the close of trading on the NASDAQ stock market. Kathy Ordoņez, Chief Executive Officer, and Alfred Merriweather, Chief Financial Officer, will lead a conference call the same day at 4:30 p.m. (ET) to discuss these results and other matters related to the business.

The management team will make prepared remarks and answer questions from securities analysts and investment professionals. Investors, securities analysts, representatives of the media and other interested parties who would like to participate should dial (800) 706-7748 or (617) 614-3473 for international callers, and enter passcode 88298626 at any time from 4:15 p.m. (ET) until the end of the call. This conference call will also be webcast. Interested parties who wish to listen to the webcast should visit the "Media and Investors" section on A digital recording will be available approximately two hours after the completion of the conference call on March 10 until March 16, 2011. Interested parties should call (888) 286-8010, or (617) 801-6888 for international callers, and enter passcode 93012110.

About Celera
Celera is a healthcare business focusing on the integration of genetic testing into routine clinical care through a combination of products and services incorporating proprietary discoveries. Berkeley HeartLab, a subsidiary of Celera, offers services to predict cardiovascular disease risk and improve patient management. Celera also commercializes a wide range of molecular diagnostic products through Abbott and has licensed other relevant diagnostic technologies developed to provide personalized disease management in cancer. Information about Celera Corporation, including reports and other information filed by the company with the Securities and Exchange Commission, is available at


David Speechly, Ph.D.
Tel: (510) 749-1853

Notice To Readers: Celera's press releases, presentations and printed remarks are included on this website for historical purposes only. The information contained in these documents should be considered accurate only as of the date of the relevant document. This information may change over time, and therefore visitors to this website should not assume that the information contained in these documents remains accurate at a later time. We do not have any current intention to update any of the information in these documents.